Xinlantai (002294.SZ): The application for clinical trials of drug SAL0140 has been accepted.

Zhijong Finance APP News, Xilantai (002294.SZ) announced that the company recently received a Notice of Acceptance issued by the National Medical Products Administration. The company's independently developed innovative small molecule drug SAL0140 tablets (project code: SAL0140) have been accepted for new indications clinical trial application.